clinical-stage biotech Archives

Digital Nasdaq billboard in Times Square highlighting Eupraxia Pharmaceuticals (NASDAQ: EPRX), its Nasdaq Global Select Market upgrade, and the upcoming eosinophilic esophagitis clinical-data catalyst.

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. September 8, 2026 231Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has moved up to the Nasdaq Global Select Market just as its lead clinical program approaches a pivotal Phase 2b interim data event. For many, the timing is rather tidy: the company is pairing greater market…

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 248Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

Comic-book-style illustration of a confident superhero in a teal suit with an “R” molecular symbol flying above a modern city skyline. Large headline text reads “Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention,” while surrounding signs reference Revolution Medicines, RVMD stock, innovation, cancer breakthrough and oncology leadership.

Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention -( $IBB $RVMD $XBI )

by John F. Heerdink, Jr. September 1, 2026 237Views 0Likes

Revolution Medicines, Inc. (NASDAQ: RVMD) seems to have crossed the line that separates a compelling biotech hypothesis from a commercial oncology story: the U.S. Food and Drug Administration approved its first medicine, RASONQUE (daraxonrasib), for certain adults with metastatic pancreatic adenocarcinoma. The approval…

Investor infographic illustrating Eli Lilly and Company (NYSE: LLY) investing up to $2.875 billion to acquire Merida Biosciences, linking Lilly’s headquarters and cash investment to Merida’s antibody-engineering candidates, precision immunology research, and projected future revenue growth.

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. September 1, 2026 219Views 0Likes

Eli Lilly and Company (NYSE: LLY) is making a confident and distinctly forward-looking move beyond its blockbuster obesity and diabetes franchises. Its agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash is a bullish vote for precision immunology:…

Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. August 17, 2026 259Views 0Likes

For patients with eosinophilic esophagitis, eating can become an exercise in calculated risk rather than a simple pleasure. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), that burden represents both an urgent medical problem and a potentially compelling opportunity to prove that…

Biotech’s Bullish Blueprint: Jazz Pharmaceuticals Buys Actio For ~$1.3B, While Eupraxia Builds for Scale -( $EPRX $JAZZ $XBI )

by John F. Heerdink, Jr. August 11, 2026 214Views 0Likes

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) offer investors two distinctly attractive versions of the same biotech proposition: value creation through disciplined execution. Jazz is deploying capital to deepen an established rare-epilepsy franchise, while Eupraxia is assembling the…

Tag: clinical-stage biotech

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention -( $IBB $RVMD $XBI )

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK )

Biotech’s Bullish Blueprint: Jazz Pharmaceuticals Buys Actio For ~$1.3B, While Eupraxia Builds for Scale -( $EPRX $JAZZ $XBI )

Your Guide To Staying Informed In The Markets